For the year ending 2025-12-31, IART had -$11,327K decrease in cash & cash equivalents over the period. -$31,052K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -516,474 |
| Depreciation and amortization | 151,832 |
| Non-cash impairment charges | 511,365 |
| Deferred income tax benefit | -66,264 |
| Share-based compensation | 18,583 |
| Amortization of debt issuance costs and expenses associated with debt refinancing | 5,605 |
| Non-cash lease expense | -987 |
| Lease incentive | 1,299 |
| Loss on disposal of property and equipment and construction in-progress | -490 |
| Change in fair value of contingent consideration and others | -21,329 |
| Accounts receivable | 485 |
| Inventories | 46,760 |
| Prepaid expenses and other current assets | 2,802 |
| Other non-current assets | -3,343 |
| Accounts payable, accrued expenses and other current liabilities | 26,724 |
| Contract liabilities | 3,400 |
| Other non-current liabilities | -17,156 |
| Net cash provided by operating activities | 50,384 |
| Purchases of property and equipment | 81,436 |
| Purchases of intangible assets | 14,202 |
| Purchases of short-term investments | 8,502 |
| Proceeds from maturities of short-term investments | 7,000 |
| Cash paid for business acquisitions, net of cash acquired | 0 |
| Net (payment) proceeds on swaps designated as net investment hedges | 10,923 |
| Net cash used in investing activities | -108,063 |
| Proceeds from borrowings of long-term indebtedness | 720,700 |
| Payments on debt | 94,906 |
| Repayments of convertible debt | 574,983 |
| Payment of debt issuance costs | 4,064 |
| Purchase of treasury stock | 221 |
| Payments for contingent considerations | 16,451 |
| Proceeds from exercise of stock options and employee stock purchase plan | 957 |
| Cash taxes paid in net equity settlement | 2,697 |
| Net cash provided by (used in) financing activities | 28,335 |
| Effect of exchange rate changes on cash and cash equivalents | 18,017 |
| Net decrease in cash and cash equivalents | -11,327 |
| Cash and cash equivalents at beginning of period | 246,375 |
| Cash and cash equivalents at end of period | 235,048 |
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)